CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer
(2010) In Nature Reviews Clinical Oncology 7(4). p.191-193- Abstract
- Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1586955
- author
- Högberg, Thomas LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nature Reviews Clinical Oncology
- volume
- 7
- issue
- 4
- pages
- 191 - 193
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000276152300009
- pmid:20354543
- scopus:77950497098
- pmid:20354543
- ISSN
- 1759-4782
- DOI
- 10.1038/nrclinonc.2010.37
- language
- English
- LU publication?
- yes
- id
- 796086d9-1ee8-4c5c-9fcc-2df37c248905 (old id 1586955)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20354543?dopt=Abstract
- date added to LUP
- 2016-04-01 10:50:58
- date last changed
- 2022-01-26 03:01:00
@misc{796086d9-1ee8-4c5c-9fcc-2df37c248905,
abstract = {{Dose-dense administration of paclitaxel as well as intraperitoneal administration of platinum and paclitaxel as first-line treatments provide similar advantages compared with standard treatment in advanced ovarian cancer. Both approaches, however, need to be confirmed by additional studies. a low dose of pegylated liposomal doxorubicin combined with carboplatin is superior to standard paclitaxel and carboplatin in relapsed platinum-sensitive ovarian cancer.}},
author = {{Högberg, Thomas}},
issn = {{1759-4782}},
language = {{eng}},
number = {{4}},
pages = {{191--193}},
publisher = {{Nature Publishing Group}},
series = {{Nature Reviews Clinical Oncology}},
title = {{CHEMOTHERAPY Current drugs still have potential in advanced ovarian cancer}},
url = {{http://dx.doi.org/10.1038/nrclinonc.2010.37}},
doi = {{10.1038/nrclinonc.2010.37}},
volume = {{7}},
year = {{2010}},
}